Predictive value of remnant-like particles cholesterol/high-density lipoprotein cholesterol ratio as a new indicator of coronary artery disease

American Heart Journal

Volumn 136, Issue 2, 1998, Pages 226-230

  Masuoka, Hiroshi ^a,c   Ishikura, Ken ^a   Kamei, Shigeru ^d   Obe, Toshihide ^a   Seko, Tetsuya ^a   Okuda, Kazuaki ^a   Koyabu, Sukenari ^a   Tsuneoka, Katsunobu ^a   Tamai, Takuya ^a   Sugawa, Masahiro ^a   Nakano, Takeshi ^b  

^a Owase General Hospital

^b MIE UNIVERSITY   (Japan)

^c Owase General Hospital   (Japan)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL;

EID: 0031848478     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1053/hj.1998.v136.89586     Document Type: Article

References (18)

1. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997;95:1-4.
2. Stein B, Fuster V, Halperin JL, Chesebro JH. Antithrombotic therapy in cardiac disease: an emerging approach based on pathogenesis and risk. Circulation 1989;80:1501-13.
3. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, et al. Lipoprotein(a) and coronary heart disease risk: a nested case control study of the Helsinki Heart Study participants. Atherosclerosis 1991;89:59-67.
4. Ridker PM, Hennekens CH, Stamfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993;270:2195-9.
5. Armstrong VM, Cremer E, Eberie A, Manke F, Shulze F, Wieland H, et al. The association between Lp(a) concentrations and angiograph-ically assessed coronary atherosclerosis. Atherosclerosis 1986;62:249-57.
6. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE. Lipoprotein(a) levels and risk of coronary heart disease in men: the lipid research clinics coronary primary prevention trial. JAMA 1994;271:999-1003.
7. Roubin GS, Harris PJ, Phil D, Bernstein L, Kelly DT. Coronary anatomy and prognosis after myocardial infarction in patients 60 years of age and younger. Circulation 1983;67:743-9.
8. Gofman JW, Glazier F, Tamplin A, Strisower B, De Lalla O. Lipoproteins, coronary heart disease, and atherosclerosis. Physiol Rev 1954;34:589-607.
9. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, et al. Cholesterol in remannt-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clinica Chimica Acta 1993;223:53-71.
10. Superko HR. Beyond LDL cholesterol reduction. Circulation 1996;94:2351-4.
11. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993,88:2762-70.
12. Sekihara T, Nakano T, Nakajima K. High postprandial plasma rem-nant-like particles-cholesterol in patients with coronary artery diseases on chronic maintenance hemodialysis. Jpn J Nephrol 1996;38:220-8.
13. Wilson PWF, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortalty: the Framingham heart study. Arteriosclerosis 1988;8:737-41.
14. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Circulation 1989;79:8-15.
15. Gram J, Jespersen J, Kluft C, Rijken DC. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial infarction. Acta Med Scand 1987;221:149-53.
16. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb 1993;13:1412-7.
17. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: a 7-year follow-up. Circulation 1993;88:2030-4.
18. 8. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991;12:157-61.